Newswire (Published: Monday, June 19, 2017, Received: Thursday, June 15, 2017, 12:21:30 PM CDT)

Word Count: 337

By a News Reporter-Staff News Editor at Clinical Trials Week -- ASCO Perspective

"This study provides strong evidence to support adding abiraterone to standard hormone therapy, primarily for men with metastatic prostate cancer," said Sumanta Kumar Pal, MD, ASCO Expert. "It adds to a growing body of evidence that establishes abiraterone as a standard of care in this setting."

CHICAGO - A clinical trial of nearly 2,000 men shows that adding abiraterone acetate (Zytiga) to a standard initial treatment regimen for high-risk, advanced prostate cancer lowers the relative risk of death by 37%. The 3-year survival rate was 76% with standard therapy alone, but 83% with standard therapy plus abiraterone. This is the largest study of abiraterone as first-line therapy for advanced prostate cancer (see also Oncology - Prostate Cancer).

The study will be featured in a press briefing today and presented at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting.

"Abiraterone not only prolonged life, but also lowered the chance of relapse by 70% and reduced the chance of serious bone complications by 50%," said lead study author Nicholas James, BSc, MBBS, PhD, Professor of Clinical Oncology at Queen Elizabeth Hospital in Birmingham, United Kingdom. "Based on the magnitude of clinical benefit, we believe that the upfront care for patients newly diagnosed with advanced prostate cancer should change."

Testosterone fuels the growth of prostate cancer cells. Androgen deprivation therapy or ADT slows prostate cancer growth by preventing testicles from making testosterone and other similar hormones (androgens). Despite ADT, other organs in the body, including the prostate gland, continue to make small amounts of testosterone and other androgens. Abiraterone stops production of both testosterone and other androgens throughout the body by targeting an enzyme that converts other hormones to androgens.

Keywords for this news article include: Therapy, Hormones, Prostatic Neoplasms, Risk and Prevention, Oncology - Prostate Cancer, American Society of Clinical Oncology.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC


The American Society of Clinical Oncology Inc
Queen Elizabeth Hospital


North America
Northern Europe
United Kingdom
United States


Science and Technology
      Scientific Research
Health and Wellness
      Medical Conditions and Diseases
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer
      Medical and Pharmaceutical Regulation
            Drug and Device Approval Process